Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer (IES)

April 21, 2014 updated by: Pfizer

Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen

To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.

Study Overview

Status

Completed

Conditions

Breast Neoplasms

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

4740

Phase

Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Argentina
- - Buenos Aires, Argentina, 1181
    - Pfizer Investigational Site
  - Cordoba, Argentina, X5000AA1
    - Pfizer Investigational Site
- Buenos Aires
  - Haedo, Buenos Aires, Argentina, 1706
    - Pfizer Investigational Site
  - San Isidro, Buenos Aires, Argentina, 1642
    - Pfizer Investigational Site
  - San Martin, Buenos Aires, Argentina, 1650
    - Pfizer Investigational Site
- Capital Federal
  - Buenos Aires, Capital Federal, Argentina, 1406
    - Pfizer Investigational Site
  - Buenos Aires, Capital Federal, Argentina
    - Pfizer Investigational Site
  - Buenos Aires, Capital Federal, Argentina, 1426
    - Pfizer Investigational Site
  - Buenos Aires, Capital Federal, Argentina, 1417
    - Pfizer Investigational Site
  - Buenos Aires, Capital Federal, Argentina, 1425
    - Pfizer Investigational Site
- Pcia. de Santa Fe
  - Rosario 2000, Pcia. de Santa Fe, Argentina
    - Pfizer Investigational Site
- Santa Fe
  - Rosario, Santa Fe, Argentina, 2000
    - Pfizer Investigational Site
Australia
- New South Wales
  - Camperdown, New South Wales, Australia, 2050
    - Pfizer Investigational Site
  - Dubbo, New South Wales, Australia, 2830
    - Pfizer Investigational Site
  - Liverpool, New South Wales, Australia, 2170
    - Pfizer Investigational Site
  - Waratah, New South Wales, Australia, 2298
    - Pfizer Investigational Site
- South Australia
  - Adelaide, South Australia, Australia, 5000
    - Pfizer Investigational Site
- Victoria
  - Bendigo, Victoria, Australia, 3552
    - Pfizer Investigational Site
  - Box Hill, Victoria, Australia, 3128
    - Pfizer Investigational Site
  - Ringwood East, Victoria, Australia, 3135
    - Pfizer Investigational Site
Belgium
- - Antwerpen, Belgium, 2020
    - Pfizer Investigational Site
  - Arlon, Belgium, 6700
    - Pfizer Investigational Site
  - Baudour, Belgium, 7331
    - Pfizer Investigational Site
  - Brasschaat, Belgium, 2930
    - Pfizer Investigational Site
  - Bruxelles, Belgium, 1000
    - Pfizer Investigational Site
  - Bruxelles, Belgium, 1180
    - Pfizer Investigational Site
  - Charleroi, Belgium, 6000
    - Pfizer Investigational Site
  - Edegem, Belgium, 2650
    - Pfizer Investigational Site
  - Genk, Belgium, 3600
    - Pfizer Investigational Site
  - Haine St. Paul, Belgium, 7100
    - Pfizer Investigational Site
  - Hasselt, Belgium, 3500
    - Pfizer Investigational Site
  - Kraainem, Belgium, 1950
    - Pfizer Investigational Site
  - La Louviere, Belgium, 7100
    - Pfizer Investigational Site
  - Leuven, Belgium, 3000
    - Pfizer Investigational Site
  - Liege, Belgium, 4000
    - Pfizer Investigational Site
  - Merksem, Belgium, 2170
    - Pfizer Investigational Site
  - Namur, Belgium, 5000
    - Pfizer Investigational Site
  - Verviers, Belgium, 4800
    - Pfizer Investigational Site
  - Wilrijk, Belgium, 2610
    - Pfizer Investigational Site
Bosnia and Herzegovina
- - Sarajevo, Bosnia and Herzegovina, 71000
    - Pfizer Investigational Site
Bulgaria
- - Plovdiv, Bulgaria, 4004
    - Pfizer Investigational Site
  - Sofia, Bulgaria, 1756
    - Pfizer Investigational Site
  - Sofia, Bulgaria, 1504
    - Pfizer Investigational Site
  - Sofia, Bulgaria, 1784
    - Pfizer Investigational Site
  - Stara Zagora, Bulgaria, 6003
    - Pfizer Investigational Site
Croatia
- - Osijek, Croatia
    - Pfizer Investigational Site
  - Split, Croatia
    - Pfizer Investigational Site
  - Zagreb, Croatia, 10000
    - Pfizer Investigational Site
  - Zagreb, Croatia
    - Pfizer Investigational Site
Czech Republic
- - Brno, Czech Republic, 656 53
    - Pfizer Investigational Site
  - Ceske Budejovice, Czech Republic, 370 87
    - Pfizer Investigational Site
  - Prague 2, Czech Republic, 12808
    - Pfizer Investigational Site
Denmark
- - Aarhus C, Denmark, 8000
    - Pfizer Investigational Site
  - Esbjerg, Denmark, 6700
    - Pfizer Investigational Site
  - Herlev, Denmark, 2730
    - Pfizer Investigational Site
  - Herning, Denmark, 7400
    - Pfizer Investigational Site
  - Hilleroed, Denmark, 3400
    - Pfizer Investigational Site
  - Koebenhavn OE, Denmark, 2100
    - Pfizer Investigational Site
  - Naestved, Denmark, 4700
    - Pfizer Investigational Site
  - Roskilde, Denmark, 4000
    - Pfizer Investigational Site
  - Vejle, Denmark, 7100
    - Pfizer Investigational Site
  - Viborg, Denmark, 8800
    - Pfizer Investigational Site
Egypt
- - Cairo, Egypt
    - Pfizer Investigational Site
Estonia
- - Tartu, Estonia, 51014
    - Pfizer Investigational Site
France
- - Angers, France, 49033 Cedex 01
    - Pfizer Investigational Site
  - Annecy Cedex, France, 74011
    - Pfizer Investigational Site
  - Avignon Cedex 2, France, 84082
    - Pfizer Investigational Site
  - Bordeaux, France, 33030 Cedex
    - Pfizer Investigational Site
  - Bordeaux, France, 33300 Cedex
    - Pfizer Investigational Site
  - Brest, France, 29609 Cedex
    - Pfizer Investigational Site
  - Caen, France, 14052 Cedex
    - Pfizer Investigational Site
  - Caen Cedex 05, France, 14076
    - Pfizer Investigational Site
  - Clermont Ferrand, France, 63011
    - Pfizer Investigational Site
  - Evreux, France, 27000
    - Pfizer Investigational Site
  - Lagny Sur Marne, France, 77405 Cedex
    - Pfizer Investigational Site
  - Le Havre, France, 76600
    - Pfizer Investigational Site
  - Le Mans, France, 72000
    - Pfizer Investigational Site
  - Lille, France, 59020 Cedex
    - Pfizer Investigational Site
  - Lyon, France, 69373
    - Pfizer Investigational Site
  - Marseille, France, 13273
    - Pfizer Investigational Site
  - Meaux, France, 77100
    - Pfizer Investigational Site
  - Montbeliard, France, 25209 Cedex
    - Pfizer Investigational Site
  - Mulhouse, France, 68070 Cedex
    - Pfizer Investigational Site
  - Nice, France, 06189
    - Pfizer Investigational Site
  - Paris, France, 75248 Cedex 5
    - Pfizer Investigational Site
  - Paris, France, 75970 Cedex 20
    - Pfizer Investigational Site
  - Perpignan, France, 66046
    - Pfizer Investigational Site
  - Rennes, France, 35042
    - Pfizer Investigational Site
  - Rouen, France, 76038 Cedex
    - Pfizer Investigational Site
  - Saint-Herblain, France, 44805
    - Pfizer Investigational Site
  - St Cloud, France, 92210
    - Pfizer Investigational Site
  - Strasbourg, France, 67091 Cedex
    - Pfizer Investigational Site
  - Toulouse, France, 31502
    - Pfizer Investigational Site
Germany
- - Berlin, Germany, 10117
    - Pfizer Investigational Site
  - Berlin, Germany, 13353
    - Pfizer Investigational Site
  - Chemnitz, Germany, 09126
    - Pfizer Investigational Site
  - Erlangen, Germany, 91054
    - Pfizer Investigational Site
  - Freiburg, Germany, 79106
    - Pfizer Investigational Site
  - Gera, Germany, 07548
    - Pfizer Investigational Site
  - Greiz, Germany, 07973
    - Pfizer Investigational Site
  - Halle, Germany, 06120
    - Pfizer Investigational Site
  - Halle, Germany, 06110
    - Pfizer Investigational Site
  - Hamburg, Germany, 22081
    - Pfizer Investigational Site
  - Hildburghausen, Germany, 98646
    - Pfizer Investigational Site
  - Leipzig, Germany, 04129
    - Pfizer Investigational Site
  - Luebeck, Germany, 23538
    - Pfizer Investigational Site
  - Muenchen, Germany, 80335
    - Pfizer Investigational Site
  - Riesa, Germany, 01589
    - Pfizer Investigational Site
  - Rodewisch, Germany, 08228
    - Pfizer Investigational Site
  - Saarbruecken, Germany, 66113
    - Pfizer Investigational Site
  - Suhl, Germany, 98527
    - Pfizer Investigational Site
  - Weiden, Germany, 92637
    - Pfizer Investigational Site
Greece
- Attiki
  - Athens, Attiki, Greece, 115 22
    - Pfizer Investigational Site
  - Athens, Attiki, Greece, 115 28
    - Pfizer Investigational Site
- Crete
  - Heraklion, Crete, Greece, 71 110
    - Pfizer Investigational Site
Hong Kong
- - New Territories, Hong Kong
    - Pfizer Investigational Site
Hungary
- - Budapest, Hungary, 1082
    - Pfizer Investigational Site
  - Budapest, Hungary, 1122
    - Pfizer Investigational Site
  - Budapest, Hungary, 1145
    - Pfizer Investigational Site
Ireland
- - Cork, Ireland
    - Pfizer Investigational Site
  - Cork, Ireland, Ireland
    - Pfizer Investigational Site
  - Dublin, Ireland
    - Pfizer Investigational Site
  - Dublin 9, Ireland
    - Pfizer Investigational Site
  - Galway, Ireland
    - Pfizer Investigational Site
Israel
- - Haifa, Israel
    - Pfizer Investigational Site
  - Haifa, Israel, 34362
    - Pfizer Investigational Site
  - Jerusalem, Israel, 91120
    - Pfizer Investigational Site
  - Jerusalem, Israel
    - Pfizer Investigational Site
  - Kfar Saba, Israel
    - Pfizer Investigational Site
  - Petah Tikva, Israel
    - Pfizer Investigational Site
  - Rehovot, Israel
    - Pfizer Investigational Site
Italy
- - Alba (CN), Italy, 12051
    - Pfizer Investigational Site
  - Aviano (PN), Italy, 33081
    - Pfizer Investigational Site
  - Bergamo, Italy, 24128
    - Pfizer Investigational Site
  - Biella, Italy, 13900
    - Pfizer Investigational Site
  - Cagliari, Italy, 09121
    - Pfizer Investigational Site
  - Casale Monferrato, AL, Italy, 15033
    - Pfizer Investigational Site
  - Correggio, Italy, 42015
    - Pfizer Investigational Site
  - Cremona, Italy, 26100
    - Pfizer Investigational Site
  - Cuneo, Italy, 12100
    - Pfizer Investigational Site
  - Fermo FM, Italy, 63023
    - Pfizer Investigational Site
  - Firenze, Italy, 50134
    - Pfizer Investigational Site
  - Genova, Italy, 16132
    - Pfizer Investigational Site
  - Genova, Italy, 16128
    - Pfizer Investigational Site
  - Lecco, Italy, 23900
    - Pfizer Investigational Site
  - Lodi, Italy, 20075
    - Pfizer Investigational Site
  - Mantova, Italy, 46100
    - Pfizer Investigational Site
  - Milano, Italy, 20133
    - Pfizer Investigational Site
  - Milano, Italy, 20121
    - Pfizer Investigational Site
  - Milano, Italy, 20141
    - Pfizer Investigational Site
  - Milano, Italy, 21053
    - Pfizer Investigational Site
  - Modena, Italy, 41100
    - Pfizer Investigational Site
  - Monserrato (CA), Italy, 09042
    - Pfizer Investigational Site
  - Monza, Italy, 20052
    - Pfizer Investigational Site
  - Napoli, Italy, 80131
    - Pfizer Investigational Site
  - Palermo, Italy, 90139
    - Pfizer Investigational Site
  - Parma, Italy, 43100
    - Pfizer Investigational Site
  - Perugia, Italy, 06132
    - Pfizer Investigational Site
  - Piacenza, Italy, 29100
    - Pfizer Investigational Site
  - Pietra Ligure (SV), Italy, 17027
    - Pfizer Investigational Site
  - Pisa, Italy, 56100
    - Pfizer Investigational Site
  - Reggio Emilia, Italy, 42100
    - Pfizer Investigational Site
  - Roma, Italy, 00148
    - Pfizer Investigational Site
  - Sassari, Italy, 07100
    - Pfizer Investigational Site
  - Terni, Italy, 05100
    - Pfizer Investigational Site
  - Thiene (VI), Italy, 36016
    - Pfizer Investigational Site
  - Torino, Italy, 10126
    - Pfizer Investigational Site
  - Tortona, Italy, 15057
    - Pfizer Investigational Site
  - Trescore Balneario BG, Italy, 24069
    - Pfizer Investigational Site
  - Treviglio (BG), Italy, 24047
    - Pfizer Investigational Site
  - Varese, Italy, 21100
    - Pfizer Investigational Site
- Modena
  - Carpi, Modena, Italy, 41012
    - Pfizer Investigational Site
Luxembourg
- - Luxembourg, Luxembourg, 1210
    - Pfizer Investigational Site
Malta
- - Floriana, Malta, VLT 14
    - Pfizer Investigational Site
Netherlands
- - Amersfoort, Netherlands, 3818 ES
    - Pfizer Investigational Site
  - Amsterdam, Netherlands, 1105 AZ
    - Pfizer Investigational Site
  - Amsterdam, Netherlands, 1066 CX
    - Pfizer Investigational Site
  - Amsterdam, Netherlands, 1061 AE
    - Pfizer Investigational Site
  - Apeldoorn, Netherlands, 7300 DS
    - Pfizer Investigational Site
  - Blaricum, Netherlands, 1261 AN
    - Pfizer Investigational Site
  - Breda, Netherlands, 4818 CK
    - Pfizer Investigational Site
  - Delft, Netherlands, 2625 AD
    - Pfizer Investigational Site
  - Den Haag, Netherlands, 2545 CH
    - Pfizer Investigational Site
  - Eindhoven, Netherlands, 5623 EJ
    - Pfizer Investigational Site
  - Enschede, Netherlands, 7513 ER
    - Pfizer Investigational Site
  - Groningen, Netherlands, 9728 NZ
    - Pfizer Investigational Site
  - Groningen, Netherlands, 9700 RM
    - Pfizer Investigational Site
  - Hengelo, Netherlands, 7555 DL
    - Pfizer Investigational Site
  - Leeuwarden, Netherlands, 8934 AD
    - Pfizer Investigational Site
  - Leiden, Netherlands, 2333 ZA
    - Pfizer Investigational Site
  - Leidschendam, Netherlands, 2262 BA
    - Pfizer Investigational Site
  - Podybus 90153, Netherlands, 5200 ME Den Bosch
    - Pfizer Investigational Site
  - Roermond, Netherlands, 6043 CV
    - Pfizer Investigational Site
  - Sittard, Netherlands, 6131 BK
    - Pfizer Investigational Site
  - Utrecht, Netherlands, 3582 KE
    - Pfizer Investigational Site
  - Veldhoven, Netherlands, 5504 DB
    - Pfizer Investigational Site
  - Zaandam, Netherlands, 1502 DV
    - Pfizer Investigational Site
New Zealand
- - Auckland, New Zealand, 1142
    - Pfizer Investigational Site
- Waikato
  - Hamilton, Waikato, New Zealand, 2021
    - Pfizer Investigational Site
Norway
- - Bergen, Norway, 5021
    - Pfizer Investigational Site
  - Bodo, Norway, 8092
    - Pfizer Investigational Site
  - Fredrikstad, Norway, 1603
    - Pfizer Investigational Site
  - Haugesund, Norway, 5390
    - Pfizer Investigational Site
  - Levanger, Norway, 7600
    - Pfizer Investigational Site
  - Mo i Rana, Norway, 8607
    - Pfizer Investigational Site
  - Molde, Norway, 6407
    - Pfizer Investigational Site
  - Notodden, Norway, 3674
    - Pfizer Investigational Site
  - Oslo, Norway
    - Pfizer Investigational Site
  - Rissa, Norway, 7100
    - Pfizer Investigational Site
  - Rjukan, Norway, 3660
    - Pfizer Investigational Site
  - Sandefjord, Norway
    - Pfizer Investigational Site
  - Tonsberg, Norway, 3103
    - Pfizer Investigational Site
  - Tromso, Norway, 9038
    - Pfizer Investigational Site
  - Tromsø, Norway, 9038
    - Pfizer Investigational Site
Peru
- - Lima, Peru, L34
    - Pfizer Investigational Site
Poland
- - Gdansk, Poland, 80-952
    - Pfizer Investigational Site
  - Gliwice, Poland, 44-101
    - Pfizer Investigational Site
  - Krakow, Poland, 31-115
    - Pfizer Investigational Site
  - Krakow, Poland, 31-826
    - Pfizer Investigational Site
  - Lodz, Poland, 93-509
    - Pfizer Investigational Site
  - Opole, Poland, 45-060
    - Pfizer Investigational Site
  - Poznan, Poland, 61-878
    - Pfizer Investigational Site
  - Sopot, Poland, 81-756
    - Pfizer Investigational Site
  - Warszawa, Poland, 02-781
    - Pfizer Investigational Site
Portugal
- - Coimbra, Portugal, 3040
    - Pfizer Investigational Site
  - Coimbra, Portugal
    - Pfizer Investigational Site
  - Evora, Portugal, 7000-811
    - Pfizer Investigational Site
Romania
- - Bucuresti, Romania, 72435
    - Pfizer Investigational Site
  - Cluj Napoca, Romania, 400015
    - Pfizer Investigational Site
  - Timisoara, Romania, 300223
    - Pfizer Investigational Site
Russian Federation
- - St. Petersburg, Russian Federation, 197758
    - Pfizer Investigational Site
Serbia
- - Belgrade, Serbia, 11000
    - Pfizer Investigational Site
  - Sremska Kamenica, Serbia, 21204
    - Pfizer Investigational Site
Slovakia
- - Banska Bystrica, Slovakia, 97517
    - Pfizer Investigational Site
  - Bratislava, Slovakia, SK-83310
    - Pfizer Investigational Site
  - Kosice, Slovakia, 041 90
    - Pfizer Investigational Site
Slovenia
- - Ljubljana, Slovenia, 1000
    - Pfizer Investigational Site
South Africa
- - Observatory, South Africa, 7925
    - Pfizer Investigational Site
- Gauteng
  - Johannesburg, Gauteng, South Africa, 2196
    - Pfizer Investigational Site
Spain
- - Albacete, Spain, 02006
    - Pfizer Investigational Site
  - Alicante, Spain, 03010
    - Pfizer Investigational Site
  - Badajoz, Spain, 06008
    - Pfizer Investigational Site
  - Badajoz, Spain, 06080
    - Pfizer Investigational Site
  - Cordoba, Spain, 14004
    - Pfizer Investigational Site
  - Guadalajara, Spain, 19002
    - Pfizer Investigational Site
  - Lleida, Spain, 25198
    - Pfizer Investigational Site
  - Madrid, Spain, 28034
    - Pfizer Investigational Site
  - Madrid, Spain, 28041
    - Pfizer Investigational Site
  - Madrid, Spain, 28040
    - Pfizer Investigational Site
  - Valencia, Spain, 46014
    - Pfizer Investigational Site
  - Zaragoza, Spain, 50009
    - Pfizer Investigational Site
- Alicante
  - Alcoy, Alicante, Spain, 03804
    - Pfizer Investigational Site
  - Elche, Alicante, Spain, 03203
    - Pfizer Investigational Site
  - San Juan de Alicante, Alicante, Spain, 03550
    - Pfizer Investigational Site
  - Sant Joan D'Alacant, Alicante, Spain, 03550
    - Pfizer Investigational Site
- Barcelona
  - Badalona, Barcelona, Spain, 08916
    - Pfizer Investigational Site
  - Badalona, Barcelona, Spain, 08911
    - Pfizer Investigational Site
  - Terrassa, Barcelona, Spain, 08227
    - Pfizer Investigational Site
  - Terrassa, Barcelona, Spain, 08221
    - Pfizer Investigational Site
- Guipuzcoa
  - San Sebastian, Guipuzcoa, Spain, 20014
    - Pfizer Investigational Site
- Huesca
  - Barbastro, Huesca, Spain, 22300
    - Pfizer Investigational Site
- Tarragona
  - Reus, Tarragona, Spain, 43201
    - Pfizer Investigational Site
Sweden
- - Boras, Sweden, 501 82
    - Pfizer Investigational Site
  - Borås, Sweden, 50182
    - Pfizer Investigational Site
  - Goteborg, Sweden, 413 45
    - Pfizer Investigational Site
  - Halmstad, Sweden, 301 85
    - Pfizer Investigational Site
  - Helsingborg, Sweden, 251 87
    - Pfizer Investigational Site
  - Kristianstad, Sweden, 291 85
    - Pfizer Investigational Site
  - Linkoping, Sweden, 581 85
    - Pfizer Investigational Site
  - Lund, Sweden, 221 85
    - Pfizer Investigational Site
  - Malmo, Sweden, 205 02
    - Pfizer Investigational Site
  - Motala, Sweden, 591 85
    - Pfizer Investigational Site
  - Norrkoping, Sweden, 601 82
    - Pfizer Investigational Site
  - Nässjö, Sweden, 575 81
    - Pfizer Investigational Site
  - Varnamo, Sweden, 331 85
    - Pfizer Investigational Site
  - Vasteras, Sweden, 721 89
    - Pfizer Investigational Site
  - Vastervik, Sweden, 59381
    - Pfizer Investigational Site
  - Vaxjo, Sweden, 351 85
    - Pfizer Investigational Site
Switzerland
- - Basel, Switzerland, CH-4031
    - Pfizer Investigational Site
  - Bellinzona, Switzerland, CH-6500
    - Pfizer Investigational Site
  - Bern, Switzerland, 3010
    - Pfizer Investigational Site
  - Bern, Switzerland, CH-3012
    - Pfizer Investigational Site
  - Genève, Switzerland, CH-1211
    - Pfizer Investigational Site
United Kingdom
- - Belfast, United Kingdom, BT97AB
    - Pfizer Investigational Site
  - Bradford, United Kingdom, BD9 6RJ
    - Pfizer Investigational Site
  - Bristol, United Kingdom, BS10 5NB
    - Pfizer Investigational Site
  - Cardiff, United Kingdom, CF14 2TL
    - Pfizer Investigational Site
  - Coventry, United Kingdom, CV2 2DX
    - Pfizer Investigational Site
  - East Kilbride, United Kingdom, G75 8RG
    - Pfizer Investigational Site
  - Huddersfield, United Kingdom, HD3 3EA
    - Pfizer Investigational Site
  - Leeds, United Kingdom, LS9 7TF
    - Pfizer Investigational Site
  - Leeds, United Kingdom, LS1 3EX
    - Pfizer Investigational Site
  - Lincoln, United Kingdom
    - Pfizer Investigational Site
  - London, United Kingdom, W6 8RF
    - Pfizer Investigational Site
  - London, United Kingdom, NW3 2QG
    - Pfizer Investigational Site
  - London, United Kingdom, N18 1QX
    - Pfizer Investigational Site
  - London, United Kingdom, SW17 0QT
    - Pfizer Investigational Site
  - London, United Kingdom, N19 5NF
    - Pfizer Investigational Site
  - Luton, United Kingdom, LU4 0DZ
    - Pfizer Investigational Site
  - Manchester, United Kingdom, M20 4BX
    - Pfizer Investigational Site
  - Sheffield, United Kingdom, S10 2SJ
    - Pfizer Investigational Site
  - Shrewsbury, United Kingdom
    - Pfizer Investigational Site
  - Somerset, United Kingdom, BA21 4AT
    - Pfizer Investigational Site
  - Southampton, United Kingdom, S016 6YD
    - Pfizer Investigational Site
  - Steeton, United Kingdom, BD20 6TD
    - Pfizer Investigational Site
  - Stoke on Trent, United Kingdom, ST4 6QG
    - Pfizer Investigational Site
  - Telford, United Kingdom, TF1 6TF
    - Pfizer Investigational Site
  - Wythenshawe, Manchester, United Kingdom, M23 9LT
    - Pfizer Investigational Site
- Cambs
  - Huntingdon, Cambs, United Kingdom, PE18 8NT
    - Pfizer Investigational Site
- Dorset
  - Bournemouth, Dorset, United Kingdom, BH7 7DW
    - Pfizer Investigational Site
- East Yorkshire
  - Hull, East Yorkshire, United Kingdom, HU16 5JQ
    - Pfizer Investigational Site
- Essex
  - Epping, Essex, United Kingdom, CM166TN
    - Pfizer Investigational Site
  - Westcliff-On-Sea, Essex, United Kingdom, SS0 0RY
    - Pfizer Investigational Site
- Gwent
  - Newport, Gwent, United Kingdom, NP6 2UB
    - Pfizer Investigational Site
- Gwynedd
  - Bangor, Gwynedd, United Kingdom, LL57 2PW
    - Pfizer Investigational Site
- Halifax
  - Salterhebble, Halifax, United Kingdom, HX6 0PW
    - Pfizer Investigational Site
- Hants
  - Gosport, Hants, United Kingdom, PO12 2AA
    - Pfizer Investigational Site
- Middlesex
  - Northwood, Middlesex, United Kingdom, HA6 2RN
    - Pfizer Investigational Site
- N. Ireland
  - Londonderry, N. Ireland, United Kingdom, BT47 1SB
    - Pfizer Investigational Site
- N. Yorkshire
  - Harrogate, N. Yorkshire, United Kingdom, HG2 7SX
    - Pfizer Investigational Site
- Somerset
  - Taunton, Somerset, United Kingdom, TA1 5DA
    - Pfizer Investigational Site
- South Wales
  - Swansea, South Wales, United Kingdom, SA2 8QA
    - Pfizer Investigational Site
- Yorkshire
  - York, Yorkshire, United Kingdom, Y03 7He
    - Pfizer Investigational Site
United States
- Alabama
  - Birmingham, Alabama, United States, 35205
    - Pfizer Investigational Site
  - Birmingham, Alabama, United States, 35213
    - Pfizer Investigational Site
  - Birmingham, Alabama, United States, 35235
    - Pfizer Investigational Site
- Arizona
  - Green Valley, Arizona, United States, 85614
    - Pfizer Investigational Site
  - Green Velley, Arizona, United States, 85614
    - Pfizer Investigational Site
  - Tucson, Arizona, United States, 85715
    - Pfizer Investigational Site
  - Tucson, Arizona, United States, 85712
    - Pfizer Investigational Site
  - Tucson, Arizona, United States, 85710
    - Pfizer Investigational Site
  - Tucson, Arizona, United States, 85704
    - Pfizer Investigational Site
  - Tucson, Arizona, United States, 85745
    - Pfizer Investigational Site
- Colorado
  - Boulder, Colorado, United States, 80304
    - Pfizer Investigational Site
  - Colorado Springs, Colorado, United States, 80909
    - Pfizer Investigational Site
  - Denver, Colorado, United States, 80218
    - Pfizer Investigational Site
  - Fort Collins, Colorado, United States, 80528
    - Pfizer Investigational Site
  - Lakewood, Colorado, United States, 80228
    - Pfizer Investigational Site
  - Thornton, Colorado, United States, 80260
    - Pfizer Investigational Site
- Florida
  - Jacksonville, Florida, United States, 32207
    - Pfizer Investigational Site
  - Jacksonville, Florida, United States, 32204
    - Pfizer Investigational Site
  - Jacksonville Beach, Florida, United States, 32250
    - Pfizer Investigational Site
  - Ocala, Florida, United States, 34474
    - Pfizer Investigational Site
  - Orange Park, Florida, United States, 32073
    - Pfizer Investigational Site
- Indiana
  - Fishers, Indiana, United States, 46038
    - Pfizer Investigational Site
  - Fishers, Indiana, United States, 46037
    - Pfizer Investigational Site
  - Indianapolis, Indiana, United States, 46227
    - Pfizer Investigational Site
  - Indianapolis, Indiana, United States, 46219
    - Pfizer Investigational Site
  - Indianapolis, Indiana, United States, IN 46219
    - Pfizer Investigational Site
- Iowa
  - Cedar Rapids, Iowa, United States, 52403
    - Pfizer Investigational Site
- Massachusetts
  - Pittsfield, Massachusetts, United States, 01201
    - Pfizer Investigational Site
- New York
  - Albany, New York, United States, 12206
    - Pfizer Investigational Site
  - Latham, New York, United States, 12110-0610
    - Pfizer Investigational Site
- Oregon
  - Portland, Oregon, United States, 97225
    - Pfizer Investigational Site
  - Portland, Oregon, United States, 97227
    - Pfizer Investigational Site
- Texas
  - Arlington, Texas, United States, 76014-2084
    - Pfizer Investigational Site
  - Bedford, Texas, United States, 76022
    - Pfizer Investigational Site
  - Dallas, Texas, United States, 75231
    - Pfizer Investigational Site
  - Dallas, Texas, United States, 75230-2510
    - Pfizer Investigational Site
  - Dallas, Texas, United States, 75246
    - Pfizer Investigational Site
  - El Paso, Texas, United States, 79902
    - Pfizer Investigational Site
  - El Paso, Texas, United States, 79915
    - Pfizer Investigational Site
  - Garland, Texas, United States, 75042
    - Pfizer Investigational Site
  - Houston, Texas, United States, 77030
    - Pfizer Investigational Site
  - Houston, Texas, United States, 77024
    - Pfizer Investigational Site
  - Houston, Texas, United States, 77074
    - Pfizer Investigational Site
  - Houston, Texas, United States, 77029
    - Pfizer Investigational Site
  - Longview, Texas, United States, 75601
    - Pfizer Investigational Site
  - McAllen, Texas, United States, 78503
    - Pfizer Investigational Site
  - Mesquite, Texas, United States, 75150
    - Pfizer Investigational Site
  - Odessa, Texas, United States, 79761
    - Pfizer Investigational Site
  - Pasadena, Texas, United States, 77502
    - Pfizer Investigational Site
  - Plano, Texas, United States, 75075-7787
    - Pfizer Investigational Site
  - San Antonio, Texas, United States, 78217
    - Pfizer Investigational Site
  - Sherman, Texas, United States, 75090
    - Pfizer Investigational Site
  - Sugar Land, Texas, United States, 77479
    - Pfizer Investigational Site
  - Tyler, Texas, United States, 75702
    - Pfizer Investigational Site
  - Weslaco, Texas, United States, 78596
    - Pfizer Investigational Site
- Washington
  - Spokane, Washington, United States, 99202
    - Pfizer Investigational Site
  - Spokane, Washington, United States, 99218
    - Pfizer Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

Female

Description

Inclusion Criteria:

postmenopausal women with histologically or cytologically confirmed primary breast adenocarcinoma, receiving tamoxifen and have been treated with tamoxifen continuously for between 2 and 3 years and one month, and still free of disease

Exclusion Criteria:

unresectable breast cancer
ER negative primary tumor

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: Double

Number of Arms

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: B	Drug: Tamoxifen Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
Experimental: A	Drug: Exemestane Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study Time Frame: Baseline up to Month 36	DFS defined as time from randomization to earliest documentation of breast cancer relapse or death from any cause. DFS at Month 36 post-randomization was defined as probability of participants alive and disease-free at 36 months after the randomization. Participants withdrawn from the study for any reason in the absence of relapse were censored at the date they were last seen. Relapse was categorized as follows: loco-regional: ipsilateral breast or axillary nodal relapse; distant: distant relapse, including supraclavicular nodes; second primary breast cancer: contralateral breast cancer, excluding ductal carcinoma in situ.	Baseline up to Month 36

Secondary Outcome Measures

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pfizer

Collaborators

International Collaborative Cancer Group

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

To obtain contact information for a study center near you, click here.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 1998

Primary Completion (Actual)

June 1, 2003

Study Completion (Actual)

March 1, 2013

Study Registration Dates

First Submitted

May 31, 2002

First Submitted That Met QC Criteria

May 31, 2002

First Posted (Estimate)

June 3, 2002

Study Record Updates

Last Update Posted (Estimate)

May 7, 2014

Last Update Submitted That Met QC Criteria

April 21, 2014

Last Verified

April 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

96-OEXE-031
A5991012

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Neoplasms

Emory University
Eisai Inc.

Terminated

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Breast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, Breast

United States
Seagen Inc.

Completed

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Triple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast Neoplasms

United States
Innocrin Pharmaceutical

Completed

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) (CLARITY-01)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the Breast

United States
G1 Therapeutics, Inc.

Terminated

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Breast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasms

United States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
Sidney Kimmel Cancer Center at Thomas Jefferson...
Celgene Corporation

Terminated

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Inflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast Cancer

United States
Dana-Farber Cancer Institute
Conquer Cancer Foundation

Recruiting

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Inflammatory Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Inflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
GlaxoSmithKline

Completed

Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer

Neoplasms, Breast

United States, Spain, Israel, Canada, Belgium, United Kingdom, France, Tunisia
GlaxoSmithKline

Completed

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

Neoplasms, Breast

United States, Canada, Germany, Spain, Taiwan, Belgium, Philippines, Israel, Hong Kong, Thailand, Pakistan, Russian Federation, Italy, Romania, China, France, Peru, United Kingdom, Czech Republic, Australia, Chile, Korea, Republic of and more
MedSIR
Hoffmann-La Roche

Completed

First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC (ATRACTIB)

Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer

Spain, France, United Kingdom, Germany, Italy

Clinical Trials on Tamoxifen

Institut Cancerologie de l'Ouest

Active, not recruiting

Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer (PRESAGE)

Breast Cancer

France
Northwestern University
National Cancer Institute (NCI)

Completed

4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ

Estrogen Receptor-positive Breast Cancer | Ductal Breast Carcinoma in Situ

United States
Seoul National University Hospital

Active, not recruiting

Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients (MORE-T)

Hormone Receptor-positive Breast Cancer | Premenopausal Breast Cancer

Korea, Republic of
European Institute of Oncology
Istituto Oncologico Veneto IRCCS; Ente Ospedaliero Ospedali Galliera; Istituto...

Not yet recruiting

Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion (TOLERANT)

Ductal Carcinoma in Situ | RAD51C Gene Mutation | RAD51D Gene Mutation | PALB2 Gene Mutation | Lobular Carcinoma in Situ | ATM Gene Mutation | CDH1 Gene Mutation | CHEK2 Gene Mutation | BRCA Mutation

Italy
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

Breast Cancer | Stage IV Breast Cancer

United States, Canada, Peru
National Cancer Center, Korea

Unknown

Decision Aids for Tamoxifen Treatment in Breast Cancer Patients

Breast Cancer
Northwestern University
National Cancer Institute (NCI); BHR Pharma, LLC

Recruiting

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

Estrogen Receptor Positive | Ductal Breast Carcinoma In Situ

United States
The Methodist Hospital Research Institute
Millennium Pharmaceuticals, Inc.

Completed

TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer (ANETT)

Estrogen Receptor Positive Breast Cancer

United States
Kafrelsheikh University

Not yet recruiting

Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus (Combination)

COVID-19
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS) at Month 36 Post-Randomization: Main Study Time Frame: Baseline up to Month 120	OS was defined as the duration from randomization to death (due to any cause). OS at Month 36 post-randomization was defined as probability of participants' survival at 36 months after the randomization. For participants who were alive, OS was censored at the last available assessment. Probability of OS at Month 36 post-randomization was reported using Kaplan-Meier estimates at Month 36 post-randomization based on 120-month follow-up data.	Baseline up to Month 120
Number of Events of Second Breast Cancer in Contralateral Breast: Main Study Time Frame: Baseline up to Month 120	Number of events of second primary breast cancer in contralateral breast (excluding ductal carcinoma in situ) were reported.	Baseline up to Month 120
Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study Time Frame: Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment	BMD measurements for Lumbar spine (LS) and Proximal Femur (Total Hip [TH]) were performed using dual energy X-ray absorptiometry (DXA) for participants who entered the bone-metabolism sub-study. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
Percent Change From Baseline in Femoral Neck and Femoral Wards Bone Mineral Density (BMD) at 6, 12 and 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study Time Frame: Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment	BMD measurements for femoral neck (FN) and femoral wards (FW) were performed using dual energy X-ray absorptiometry (DXA) for participants who entered the bone-metabolism sub-study. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) T-scores at 6, 12 and 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study Time Frame: Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment	BMD measurements for Lumbar spine (LS) and Proximal Femur (Total Hip [TH]) were performed using dual energy X-ray absorptiometry (DXA) for participants who entered the bone-metabolism sub-study. Results were scored as T-score. T-score indicated how many standard deviations higher or lower participant's value was when compared to the young normal reference mean. Using the World Health Organization (WHO) criteria for osteoporosis, a T-score of greater than or equal to (>=)-1.0 was classified as normal, a T-score of greater than -2.5 to less than -1.0 as osteopenic, and a T-score less than or equal to (<=)-2.5 as osteoporotic. Here 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
Percentage of Bone Specific Alkaline Phosphatase (BAP) Serum Concentration Relative to Baseline: Bone Metabolism Sub-study Time Frame: Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment	Bone specific alkaline phosphatase (BAP) serum concentration analyzed using enzyme immuno assay (EIA) at post-baseline time points was expressed as percentage of baseline BAP serum concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Percentage of C-Terminal Telopeptide (CTX) Serum Concentration Relative to Baseline: Bone Metabolism Sub-study Time Frame: Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment	C-terminal telopeptide (CTX) serum concentration analyzed using competitive enzyme-linked immunosorbent assay (ELISA) at post-baseline time points was expressed as percentage of baseline CTX serum concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Percentage of Osteocalcin (OC) and Procollagen T1 C-Peptide (PICP) Serum Concentration Relative to Baseline: Bone Metabolism Sub-study Time Frame: Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment	Osteocalcin (OC) serum concentration analyzed using ELISA and procollagen T1 c-peptide (PICP) serum concentration analyzed using sandwich EIA at post-baseline time points was expressed as percentage of baseline OC serum concentration and baseline PICP serum concentration, respectively. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points, for each group respectively.	Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Percentage of Deoxy-pyridinoline (DPD) Urine Concentration Relative to Baseline: Bone Metabolism Sub-study Time Frame: Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment	Deoxy-pyridinoline (DPD) urine concentration (adjusted for urinary creatinine) analyzed using competitive EIA at post-baseline time points was expressed as percentage of baseline DPD urine concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Percentage of N-telopeptide of Type 1 Collagen (NTX) Urine Concentration Relative to Baseline: Bone Metabolism Sub-study Time Frame: Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment	N-telopeptide of Type 1 collagen (NTX) urine concentration (adjusted for urinary creatinine) analyzed using competitive inhibition EIA at post-baseline time points was expressed as percentage of baseline NTX urine concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Number of Participants With Fracture: Bone Metabolism Sub-study Time Frame: Baseline up to 24 months post-treatment		Baseline up to 24 months post-treatment
Change From Baseline in Treatment Outcome Index (TOI) at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study Time Frame: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization	The TOI was defined as the sum of 23 items based on following Functional Assessment of Cancer Therapy - Breast version [FACT-B] subscales: Physical well-being (7 items), Functional well-being (7 items), Breast cancer subscale (9 items). Each item was scaled from 0='Not at all' to 4='Very much'. Total TOI score ranged from 0 to 92, where higher TOI score indicated better health-related quality of life (QoL). A change of five points in the TOI scores was considered clinically meaningful. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. Results for 30, 36, 48, 60 months were not reported because data for these time points was only summarized as graphical presentation.	Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Functional Assessment of Cancer Therapy - Endocrine Subscale (FACT-ES) Total Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study Time Frame: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization	The FACT-ES assessed health-related QoL in participants with breast cancer. ES subscale comprised of 18 items (hot flushes,cold sweats,night sweats, vaginal discharge,vaginal irritation,vaginal bleeding,vaginal dryness,discomfort with intercourse,lost interest in sex,gained weight,light headed/dizzy,vomiting,had diarrhea,headaches,felt bloated,breast tenderness,mood swings, felt irritable).Participants indicated how true a statement was for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total FACT-ES score was calculated as sum of all the 18 items and ranged from 0 to 72, where higher score indicated better QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Total Functional Assessment of Cancer Therapy - General Breast and Endocrine (FACT-GBE) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study Time Frame: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization	FACT-GBE assessed health-related quality of life (QoL) in participants with breast cancer. It consisted of 56 items,summarized to 7 subscales(subscale 1 to 6 constituted total FACT-B and subscale 7 constituted total ES):physical well-being(7 items), social/family well-being(7 items),relationship with doctor (2 items),emotional well-being(6 items),functional well-being(7 items),breast cancer subscale(9 items),endocrine symptoms(18 items). Participants indicated how true a statement had been for them using 5-point scale from 0(not at all) to 4(very much). For items that were negatively framed,scores were reversed for analysis so that higher scores equated to good QoL. Total FACT-GBE score=sum of all 56 items(range 0 to 224, where higher score indicated better QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Physical Well-Being (PWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study Time Frame: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization	The PWB subscale assessed physical well-being related QoL in participants with breast cancer. PWB subscale comprised of 7 items (energy lack, nausea, family needs, pain, side effects, felt ill, forced to stay in bed). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total PWB score was calculated as the sum of all the 7 items and ranged from 0 to 28, where higher score indicated better physical well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Social/Family Well-Being (SWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study Time Frame: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization	The SWB subscale assessed social/family well-being related QoL in participants with breast cancer. SWB subscale comprised of 7 items (distant from friends, emotional support, support from friends, family acceptance, family communication, close to main support, sexual satisfaction). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total SWB score was calculated as the sum of all the 7 items and ranged from 0 to 28, where higher score indicated better social/family well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Relationship With Doctor (RWD) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Substudy Time Frame: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization	The RWD subscale assessed relationship with doctor in participants with breast cancer. RWD subscale comprised of 2 items (confidence in doctors, doctor answered questions). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). Total RWD score was calculated as the sum of the 2 items and ranged from 0 to 8, where higher score indicated better relationship with doctor. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Emotional Well-Being (EWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study Time Frame: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization	The EWB subscale assessed emotional well-being related QoL in participants with breast cancer. EWB subscale comprised of 6 items (felt sad, proud of coping, lost hope, felt nervous, worried about dying, worried about condition worsening). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equate to a good QoL. Total EWB score was calculated as the sum of the 6 items and ranged from 0 to 24, where higher score indicated better emotional well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Functional Well-Being (FWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study Time Frame: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization	The FWB subscale assessed functional well-being related QoL in participants with breast cancer. FWB subscale comprised of 7 items (able to work, work fulfilled, able to enjoy life, acceptance of illness, sleeping well, enjoyed normal fun activities, contented with QoL). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). Total FWB score was calculated as the sum of the 7 items and ranged from 0 to 28, where higher score indicated better functional well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Breast Cancer Subscale (BCS) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study Time Frame: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization	The BCS subscale assessed health related QoL in participants with breast cancer. BCS subscale comprised of 9 items (short of breath, self-conscious dress, tender/swollen arms, sexually attractive, bothered by hair loss, worried about familial risk, worried about family stress, bothered by weight change, able to feel like a woman). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total BCS score was calculated as the sum of the 9 items and ranged from 0 to 36, where higher score indicated better QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Number of Participants With Severe Endocrine Symptoms: QoL Sub-study Time Frame: Baseline up to 24 months after randomization	Participants indicated prevalence of an endocrine subscale items using a 5-point scale, where 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much). Endocrine items were grouped in five categories vasomotor (hot flushes, cold sweats, night sweats, sleeping difficulties), neuropsychological (lack of energy, nervous feeling, lightheaded/dizzy, headaches, mood swings, feeling irritable), gastrointestinal symptoms (nausea, gained weight, vomiting, diarrhea, bloated feeling), gynecological symptoms (vaginal discharge, vaginal irritation, vaginal bleeding, vaginal dryness, discomfort with intercourse, lost interest in sex, breast tenderness) and other symptoms (pain, feeling ill, side effects). Number of participants who reported severe endocrine symptoms (defined as response categories "quite a bit" and "very much") were presented.	Baseline up to 24 months after randomization
Percentage of Participants With Endometrial Thickness Greater Than or Equal to (>=) 5 Millimeter (mm): Endometrial Sub-study Time Frame: 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment	Endometrial thickness was assessed using transvaginal ultrasound examination. 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Endometrial Thickness: Endometrial Sub-study Time Frame: Baseline, 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment	Endometrial thickness was assessed using transvaginal ultrasound examination. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	Baseline, 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Uterine and Overall Ovary Volume: Endometrial Sub-study Time Frame: 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment	Uterine volume (UV) and ovarian volume was estimated using ultrasonography. Uterine volume = (longitudinal diameter * transverse diameter * anteroposterior diameter of uterus)/(21000). Ovary volume = [(longitudinal diameter transverse diameter * anteroposterior diameter of ovary) * 3.14]/(6*1000). Overall ovary volume (OV) is calculated as the sum of the right and left ovary volume. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.	6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Number of Participants With Polyps, Fibroids and Ovarian Cysts: Endometrial Sub-study Time Frame: 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment	Number of participants with presence of polyps (POL) and fibroids (FIB) at post-baseline time points compared to the baseline (BL) status of 'yes', 'no' or 'missing' (that is, participants reporting POL/FIB at post-baseline time points who had yes, no or missing POL/FIB status at baseline, respectively) were presented. Result for number of participants with ovarian cysts was not analyzed at post-baseline time points as very few participants reported ovarian cysts at baseline.	6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Percentage of Participants With at Least 1 Gynecological Symptoms: Endometrial Sub-study Time Frame: Baseline up to 24 months post-treatment	Gynecological symptoms included bleeding/spotting, pelvic pain, leucorrhoea and vaginal itching.	Baseline up to 24 months post-treatment
Number of Participants With Histological Findings: Endometrial Sub-study Time Frame: Baseline up to 24 months post-treatment		Baseline up to 24 months post-treatment

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer (IES)

Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen

Study Overview

Status

Conditions

Intervention / Treatment

Study Type

Enrollment (Actual)

Phase

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Genders Eligible for Study

Description

Study Plan

How is the study designed?

Design Details

Number of Arms

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Collaborators

Publications and helpful links

Helpful Links

Study record dates

Study Major Dates

Study Start

Primary Completion (Actual)

Study Completion (Actual)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Estimate)

Study Record Updates

Last Update Posted (Estimate)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Clinical Trials on Breast Neoplasms

Clinical Trials on Tamoxifen

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations